"People with HIV (PWH) face many challenges in obtaining HIV care: transportation issues, travel distance, competing life events, etc. Long-acting (LA)-injectable antiretrovirals (ART) could help curb some of these barriers. This project aimed to determine which patients seen at the MU outpatient HIV clinic would be candidates to receive the LA-injectable ART Cabotegravir/Rilpivirine (Cabenuva) as an alternative to a standard oral daily regimen in order to promote further HIV medication adherence."--Introduction
